539820-74-1

Basic information

• Product Name: 3(2H)-Pyridazinone, 4,5-dihydro-6-(4-methoxyphenyl)-5-methyl-
• CAS NO: 539820-74-1
• Molecular Formula: C12H14N2O2
• Molecular Weight: 218.255
• Mol File: 539820-74-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3(2H)-Pyridazinone, 4,5-dihydro-6-(4-methoxyphenyl)-5-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 3(2H)-Pyridazinone, 4,5-dihydro-6-(4-methoxyphenyl)-5-methyl-(539820-74-1)
• EPA Substance Registry System: 3(2H)-Pyridazinone, 4,5-dihydro-6-(4-methoxyphenyl)-5-methyl-(539820-74-1)

Safety Data

• Hazardous Substances Data: 539820-74-1(Hazardous Substances Data)

Upstream product

• 539820-72-9 ethyl 2-ethoxycarbonyl-3-(4-methoxybenzoyl)butanoate 
• 121-97-1 4-Methoxypropiophenone 
• 21086-33-9 2-bromo-1-(4-methoxyphenyl)-1-propanone 
• 5717-17-9 3-(4'-methoxybenzoyl)-3-methylpropionic acid 

Downstream Products

• 127867-89-4 6-(4-methoxyphenyl)-5-methylpyridazin-3(2H)-one 
• 1010801-79-2 C₂₉H₂₉F₃N₆O₄ 
• 103416-88-2 6-(4-hydroxyphenyl)-5-methyl-4,5-dihydro-2H-pyridazin-3-one 

Relevant articles and documents

PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT

It is to provide a novel pyridazinone derivative represented by the following general formula (1), which is useful as a pharmaceutical and has a phosphodiesterase inhibitory action: wherein R1 represents H or C1-6 alkyl, each of R2 and R3 represents H, X, C1-6 alkoxy, Z represents O or S, and A represents AA or BB, wherein AA represents: and BB represents: wherein R4 represents H or C1-6 alkyl, and each of R5 and R6 represents C1-6 alkyl.

Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: A novel series of potent dual PDE3/PDE4 inhibitory agents

In this study, the synthesis and in vitro and in vivo pharmacological investigations of a new series of phthalazinone/pyridazinone hybrids with both PDE3 and PDE4 inhibitory activities are described. These compounds combine the pharmacophores of recently discovered 4a,5,8,-8a-tetrahydro-2H-phthalazin-1-one-type inhibitors of PDE4 and the well-known 2H-pyridazin-3-one-type PDE3 inhibitors such as the tetrahydrobenzimidazoles. Most of the synthesized compounds are pharmacologically spoken PDE3/PDE4 hybrids. All hybrids show potent PDE4 inhibitory activity (pIC50 = 7.0-8.7), whereas the pIC50 values for inhibition of PDE3 vary from 5.4 to 7.5. In general, analogues with a 5-methyl-4,5-dihydropyridazinone moiety exhibit the highest PDE3 inhibitory activities. The highest in vivo antiinflammatory activity is displayed by phthalazinones 43 and 44 showing, at a dose of 30μmol/kg po, 46% inhibition of arachidonic acid (AA) induced mouse ear edema. No correlation was found between the in vitro PDE3 and/or PDE4 inhibitory activity and the in vivo antiinflammatory capacity after oral dosing.